Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2026 13:00 ET | Source: DelveInsight Business Research LLP

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight

New York, USA, April 13, 2026 (GLOBE NEWSWIRE) -- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such...
November 04, 2025 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 ...
October 08, 2025 10:29 ET | Source: EnteroTrack

Medicare Now Reimbursing for EnteroTrack’s Esophageal String Test®, Expanding Access to Patients with Eosinophilic Esophagitis

Medicare now reimburses EnteroTrack’s Esophageal String Test®, expanding patient access to minimally invasive EoE monitoring nationwide.
September 02, 2025 08:00 ET | Source: Eupraxia Pharmaceuticals Inc.

First Set of 1-Year Clinical Results from RESOLVE Trial in Eosinophilic Esophagitis (EoE), Durable and Sustained Symptom & Tissue Responses after Dosing with EP-104GI

Eupraxia Pharmaceuticals Reports Initial One Year Clinical Results from RESOLVE Trial in Patients with Eosinophilic Esophagitis (EoE).
December 17, 2024 05:00 ET | Source: EsoCap AG

EsoCap announces publication of comprehensive Phase II results demonstrating ESO-101’s effectiveness in eosinophilic esophagitis

Detailed results of the ACESO Phase II study published in the peer-reviewed medical journal Alimentary Pharmacology & TherapeuticsESO-101 leverages EsoCap’s unique drug delivery technology to...
September 20, 2024 07:45 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared to placebo, consistent with improvements seen in...
June 26, 2024 17:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only...
February 09, 2024 05:30 ET | Source: Growth Plus Reports

Eosinophilic Esophagitis Market Size to Surpass US$ 941.8 million by 2031 - Growth Plus Reports

Pune, Feb. 09, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Eosinophilic Esophagitis Market is expected to clock US$ 941.8 million by 2031 and...
January 25, 2024 14:29 ET | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...
December 05, 2023 03:00 ET | Source: EsoCap AG

EsoCap reports positive topline results from ACESO Phase II trial investigating ESO-101 in eosinophilic esophagitis

ESO-101, EsoCap's lead product candidate, consists of a capsule with a rolled-up, thin mucoadhesive film with the anti-inflammatory corticosteroid, mometasone furoateEsoCap's novel targeted delivery...